Skip to main content

ORIGINAL RESEARCH article

Front. Cell. Infect. Microbiol.

Sec. Clinical Microbiology

Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1589236

This article is part of the Research Topic Perspectives in Clinical Microbiology for Combating Multi-drug Resistant Bacterial Infections: 2024/2025 View all 7 articles

Rapid detection of drug resistance in Mycobacterium tuberculosis clinical isolates for first-line antitubercular drugs by using a novel reporter mycobacteriophage

Provisionally accepted
Ruiqing Ma Ruiqing Ma 1*Mingquan Guo Mingquan Guo 1Yan Wang Yan Wang 2Juntao Sun Juntao Sun 3Chengcheng Qian Chengcheng Qian 4Douglas B Lowrie Douglas B Lowrie 1Fei Niu Fei Niu 1Juan Wu Juan Wu 1Zhidong Hu Zhidong Hu 1Xiao-Yong Fan Xiao-Yong Fan 1
  • 1 Shanghai Public Health Clinical Center, Fudan University, Shanghai, China
  • 2 Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
  • 3 Department of Gastroenterology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China, Jinan, China
  • 4 Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    The emergence of drug resistance presents a major challenge for the treatment of tuberculosis (TB). Reporter phage can provide an effective method for drug susceptibility testing (DST) of Mycobacterium tuberculosis (Mtb), but limited for parts of antitubercular drugs and the process of operation is usually time-consuming. Herein, we developed a new, sensitive, reporter phage with optimized method to detect drug susceptibility of Mtb clinical isolates for all first-line antitubercular drugs. The PfurAma promoter and nanoluciferase (Nluc) reporter sequences were integrated into the genome of the TM4 mycobacteriophage to generate a reporter phage, designated φFN. By optimizing concentration of Mtb, Tween 80 and drugs, we have established an efficient workflow for φFN-based DST of Mtb that provides results for four first-line antitubercular drugs within 72 hours. A total of 71 clinical isolates were tested and yielded significant relative luminescent units (RLUs), and their resistance to rifampin (RIF), isoniazid (INH), streptomycin (STR), and EMB were compared to the conventional DST by MGIT 960. The comparative sensitivities of φFN DST detection were 100%, 93.9%, 97.2%, and 81.3%, respectively; and the relative specificities were 98.1%, 97.4%, 97.1%, and 96.4%, respectively. The remaining luminescence rate (RLR) in the φFN DST assay showed correlation with minimum inhibitory concentration (MIC). The φFN DST assay provides an efficient phage-based workflow to detect drugresistant Mtb for four first-line antitubercular drugs within 3 days.

    Keywords: Mycobacterium tuberculosis, reporter phage φFN, Drug susceptibility testing (DST), first-line antitubercular drugs, Drug Resistance

    Received: 07 Mar 2025; Accepted: 26 Mar 2025.

    Copyright: © 2025 Ma, Guo, Wang, Sun, Qian, Lowrie, Niu, Wu, Hu and Fan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ruiqing Ma, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    95% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more